Buy Jupiter Life Line Hospitals Ltd For Target Rs. 410 by Choice Institutional Equities Ltd
Expansion Pipeline Drives Long-term Growth:
Despite near-term margin pressure from the Dombivli hospital, JLHL's robust expansion pipeline positions it for sustained growth. As new hospitals mature, rising occupancies and operating leverage are expected to accelerate earnings, creating a significantly larger revenue and profitability base over the next few years
View and Valuation:
We expect Revenue/EBITDA/APAT to expand at a CAGR of 23.4%/23.1%/25.4% over FY26–29E. Valuing the stock on DCF (including the BKC expansion plan), we revise our target price to INR 410 (from INR 329) due to earlier ramp-up of new hospitals and maintain ‘BUY’ rating on the stock. This equates to an implied PE of 42x on FY28 EPS and PEG of ~2.0.
Dombivli ramp-up is tracking guidance, de-risking the path to breakeven:
In Q1FY27, Dombivli completed its first full quarter of operations, dragging EBITDA by INR 9.5 Cr, pretty much in line with anticipation. Occupancy already stands at 25-30%, expected to improve every quarter. Management reaffirmed its 1.5-2 year EBITDA breakeven guidance and its steady-state monthly loss guidance of INR 2-3 Cr, resisting pressure to revise despite early positive signs. With fixed costs capped near INR 6-7 Cr/month and insurance empanelment still pending (a further occupancy lever), the ramp-up trajectory offers a credible, guided path to profitability.
Mature hospitals (Thane, Pune) are compounding margin expansion story:
This quarter's consolidated EBITDA margin came in at 19.3% on INR 411 Cr of income, with base business profitability (Thane/Pune) improving sharply to 25- 26% over the last two quarters, up from historical levels. Pune, still at mid-60% occupancy versus a ~75% ceiling, has ~15% of occupancy-driven growth left before plateauing into inflation-linked growth alone. Thane has already reached a mature margin profile. As newer units mature, highest-ever ARPOB (currently INR 73,500) grows faster than inflation due to case-mix shift toward tertiary/quaternary care, then settles into inflation-linked growth, a repeatable, de-risked profitability curve across the portfolio.
Balance sheet funds growth without near-term dilution:
The company sits at ~INR 500 Cr of debt against ~INR 500 Cr of cash, effectively zero net debt. Management expects internal accruals and existing cash to fund Capex for the next few years, with debt only considered toward the tail end of the current expansion cycle. This gives JLHL significant balance-sheet optionality to fund its three-hospital pipeline and the recently acquired IV-fluids backward-integration unit (INR35-40 Cr) organically minimizing dilution or refinancing risk through the build-out phase.
For Detailed Report With Disclaimer Visit. https://choicebroking.in/disclaimer
SEBI Registration no.: INZ 000160131
